Data on two commercially available rapid assays for the detection of IgG and IgM antibodies to SARS-CoV-2 compared to ELISA

This data record contains a single dataset, <b>data_SARS-CoV-2_POC_study.xlsx</b>, in .<b>xlsx</b> file format.The file contains data from blood serum and whole blood of 130 participants, who were tested with the NADAL COVID-19 IgG/IgM Rapid Test and the mö-screen 2019-NCOV Corona Virus Test against a validated ELISA test. Infection status was evaluated using real-time polymerase-chain-reaction (PCR).The file also includes the category of each participant. Each participant was classified as either category I (“High-risk-exposure”, i.e. being within less than two meters for a prolonged period of time, or close contact during aerosol generating procedures) or category II (“Low-risk-exposure”, i.e. contact beyond a distance of two meters for less than 15 minutes).<br><b>Clinical trial registration number</b>: DRKS00022083<b><br></b><b>Ethics approval and patient consent:</b> Sample collection was performed with approval and in accordance with the local ethics authority of the study site (Ethic Committee of the Federal State Lower Austria, GS1-EK-3/168-2020). All participants gave their written informed consent for providing samples and data analysis.<br><b>Study aims and methodology</b>: The aim of this study was to evaluate the diagnostic accuracy of rapid antibody detection tests compared to a validated laboratory-based enzyme-linked immunosorbent assay (ELISA) and to investigate infections amongst healthcare workers (HCWs) after unprotected close contact to COVID-19 patients.All participants were recruited at the University Hospital Krems, Austria, in April 2020. The participants belonged to hospital staff (e.g. medical doctors, nurses, biomedical analysts, and physiotherapists), with known close contact to COVID-19 patients without wearing personal protective equipment, mainly due to a primarily negative (but repeated and subsequently positive) RT-PCR-result and/or lack of symptoms of the patients.A nasopharyngeal swab sample and blood samples were collected simultaneously from every participant. Five participants already fully recovered from a previous RT-PCR-confirmed COVID-19 infection, with a mean time from diagnosis to study inclusion of 39 days. Test samples were obtained in the same manner as from the collective with unknown status (n= 125).The following techniques are described in more detail in the related article: real-time RT-PCR assay, enzyme-linked immunosorbent assay (ELISA), and lateral flow chromatographic immunoassay (point-of-care antibody test).<br>